The George Institute for Global Health, University of Oxford, Oxford OX1 2BQ, UK.
The George Institute for Global Health, University of New South Wales, Sydney, NSW 2050, Australia.
Int J Environ Res Public Health. 2019 Apr 1;16(7):1165. doi: 10.3390/ijerph16071165.
Age-standardised rates of cardiovascular disease (CVD) are substantially higher in men than women. This explains why CVD has traditionally been seen as a "man's problem". However, CVD is the leading cause of death in women, worldwide, and is one of the most common causes of disability-adjusted life-years lost. In general, this is under-recognised and, in several ways, women are disadvantaged in terms of CVD. Both in primary and secondary prevention, there is evidence that women are undertreated, compared to men. Women often experience heart disease in a different way compared to men, and lack of recognition of this has been shown to have adverse consequences. Female patients of male cardiac physicians have been found to have worse outcomes than their male counterparts, with no such gender differential for female cardiologists. Clinical trials in CVD primarily recruit male patients, yet, it is well recognised that some drugs act differently in women and men. Diabetes and smoking, and perhaps other risk factors, confer a greater proportional excess cardiovascular risk to women than to men, whilst adverse pregnancies and factors concerned with the female reproductive cycle give women added vulnerability to CVD. However, women's health research is skewed towards mother and child health, an area where, arguably, the greatest public health gains have already been made, and breast cancer. Hence there is a need to redefine what is meant by "women's health" to encompass the whole lifecycle, with a stronger emphasis on CVD and other non-communicable diseases. Sex-specific analyses of research data should be the norm, whenever feasible.
心血管疾病(CVD)的年龄标准化发病率在男性中明显高于女性。这就是为什么 CVD 一直被视为“男性问题”。然而,CVD 是全球女性的主要死因之一,也是失去调整生命年的最常见原因之一。总的来说,这一点未得到充分认识,而且女性在 CVD 方面处于多种劣势地位。无论是在一级预防还是二级预防中,都有证据表明,与男性相比,女性的治疗不足。女性的心脏病发作方式通常与男性不同,而且缺乏对这种差异的认识已被证明会产生不良后果。与男性相比,男性心脏病医生的女性患者的预后更差,而女性心脏病专家则没有这种性别差异。CVD 的临床试验主要招募男性患者,但众所周知,某些药物在女性和男性中的作用不同。糖尿病和吸烟,以及其他一些可能的风险因素,对女性的心血管风险增加比例大于男性,而不良妊娠和与女性生殖周期相关的因素使女性更容易患上 CVD。然而,女性健康研究偏向于母婴健康,这是一个可以说已经取得了最大公共卫生收益的领域,以及乳腺癌。因此,有必要重新定义“妇女健康”的含义,将整个生命周期包括在内,并更加强调 CVD 和其他非传染性疾病。只要可行,就应将对研究数据进行的性别特异性分析作为规范。